Northside Capital Management LLC Purchases 49,189 Shares of Boston Scientific Corporation $BSX

Key Points

• Northside Capital Management increased its Boston Scientific position by 44.2% in the second quarter, acquiring 49,189 shares and bringing its holdings to 160,366 shares valued at approximately $6.84 million. Institutional investors collectively own 89.07% of the company.
• Analyst sentiment remains generally positive, with 24 Buy, five Hold, and two Sell ratings. Boston Scientific has a consensus “Moderate Buy” rating and an average price target of $71.62.
• Boston Scientific exceeded quarterly expectations with adjusted EPS of $0.86 and revenue of $5.44 billion, while revenue rose 7.5% year over year. The company also authorized a $5 billion share-buyback program, covering up to 6.4% of outstanding shares.

Northside Capital Management LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 44.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 160,366 shares of the medical equipment provider's stock after acquiring an additional 49,189 shares during the period. Northside Capital Management LLC's holdings in Boston Scientific were worth $6,844,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FWL Investment Management LLC purchased a new stake in Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific during the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific during the 4th quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Boston Scientific during the 1st quarter valued at $28,000. Finally, Sfam LLC purchased a new stake in shares of Boston Scientific in the 4th quarter worth about $29,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the subject of several research reports. BTIG Research decreased their price target on shares of Boston Scientific from $65.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, July 29th. Weiss Ratings lowered shares of Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Tuesday, July 7th. Leerink Partners set a $60.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Barclays lowered their target price on shares of Boston Scientific from $96.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 28th. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Boston Scientific has a consensus rating of "Moderate Buy" and an average price target of $71.62.

Insider Activity at Boston Scientific

In related news, Director Cheryl Pegus purchased 1,770 shares of the company's stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director directly owned 1,770 shares in the company, valued at $99,987.30. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the firm's stock in a transaction dated Friday, July 31st. The shares were bought at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares of the company's stock, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 204,322 shares of company stock worth $9,939,221. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Up 1.5%

BSX stock opened at $51.19 on Wednesday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50. The business has a fifty day moving average price of $45.87 and a 200-day moving average price of $59.97. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a market capitalization of $74.19 billion, a P/E ratio of 20.73, a P/E/G ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the company posted $0.75 earnings per share. The company's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities analysts forecast that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has initiated a share buyback program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source